Theme

AstraZeneca

AZNHealthcare
11,248.00GBX
-1.30%
Market Cap
174.37B
Volume
2.24M
98% of avg
P/E Ratio
1557.89
EPS (TTM)
7.22
Beta
0.17
Day Range
11,224.00p - 11,450.00p
52 Week Range
9,573.50p11,248.00p12,256.00p
11,248.00p

Upcoming Events

Early Q4 2025
Regulatory submission for anselamimab in AL amyloidosis
High Impact Event
24 October 2025
TULIP-SC interim results to be presented at ACR Convergence 2025 annual meeting
High Impact Event
6 November 2025
Announcement of 9M and Q3 2025 results
High Impact Event
Q4 2025
Presentation of 52-week data from CALYPSO trial
High Impact Event
2026
Potential regulatory submission for eneboparatide
High Impact Event
10 February 2026
Announcement of FY and Q4 2025 results
High Impact Event
AZN
NEUTRAL

AstraZeneca's Saphnelo meets primary endpoint in TULIP-SC trial for systemic lupus erythematosus

The biopharmaceutical company reports that its Saphnelo treatment met the primary endpoint in a Phase III trial for systemic lupus erythematosus, demonstrating a statistically significant and clinically meaningful reduction in disease activity.

AZN
NEUTRAL

AstraZeneca's Fasenra fails to meet primary endpoint in COPD trial

The pharmaceutical company's trial of a drug for COPD did not meet its primary endpoint, though it showed some numerical improvement.

AZN
NEUTRAL

AstraZeneca Provides Update on Holding Notification

The pharmaceutical company has issued a notification regarding a previous shareholding disclosure that was provided in error.

AZN
NEUTRAL

AstraZeneca Announces Change in Shareholding

The pharmaceutical company has received notification of a change in shareholding by The Capital Group Companies, Inc.

AZN
NEUTRAL

AstraZeneca Announces Change in Shareholding

The pharmaceutical company has received notification of a change in shareholding by The Capital Group Companies, Inc.

AZN
NEUTRAL

AstraZeneca Announces Director/PDMR Shareholding

The pharmaceutical company has disclosed a sale of ordinary shares by its Chief Financial Officer.

AZN
NEUTRAL

AstraZeneca Announces Change in Shareholding

The pharmaceutical company has received notification of a change in major shareholding.

AZN
NEUTRAL

AstraZeneca Announces Change in Major Shareholding

The healthcare company has reported a change in major shareholding, with The Capital Group Companies, Inc. reducing its stake in the firm.

AZN
GOOD

AstraZeneca Reports Strong H1 2025 Results with 11% Revenue Growth

The biopharmaceutical giant reported an 11% increase in total revenue and a 16% rise in core earnings per share for H1 2025, backed by strong performance across all major regions and positive pipeline developments.

AZN
NEUTRAL

AstraZeneca's Gefurulimab Meets Phase III Endpoints for Generalized Myasthenia Gravis

The biopharmaceutical company announced that its novel nanobody treatment for a rare autoimmune disorder met primary and secondary endpoints in a Phase III trial.